Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel therapies to treat patients serious and rare genetic skin diseases.

WAYNE, PA — Palvella Therapeutics, Inc. has completed its merger with Pieris Pharmaceuticals, Inc., forming a unified company under the name Palvella Therapeutics, Inc. Shares of the newly ...

Palvella Therapeutics to debut on Nasdaq under the ticker symbol “PVLA” as a publicly traded rare disease biopharmaceutical company advancing a late clinical-stage pipeline and a ...

Palvella Therapeutics (PVLA) announced results from the Phase 2 study of QTORIN 3.9% rapamycin anhydrous gel for the treatment of microcystic lymphatic malformations were published in the Journal ...

Andrew Fein, an analyst from H.C. Wainwright, has initiated a new Buy rating on Palvella Therapeutics (PVLA). Discover the latest stocks recommended by top Wall Street analysts, all in one place ...

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports.

Palvella Therapeutics Announces First Patients Dosed in Phase 2 TOIVA Clinical Trial of QTORIN™ ... Palvella Therapeutics Inc. - (GLOBE NEWSWIRE) Jan 8, 2025 ...

Find the latest Palvella Therapeutics, Inc. PVLA analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports.

Read Our Latest Analysis on PVLA Palvella Therapeutics Stock Performance PVLA opened at $12.00 on Monday. Palvella Therapeutics has a 52 week low of $6.20 and a 52 week high of $22.32. The company ...

WAYNE, Pa. - Palvella Therapeutics Inc. (NASDAQ:PVLA), whose stock has gained nearly 19% year-to-date and currently trades at $14.25, announced today that results from its Phase 2... ByInvesting ...

Palvella Therapeutics, Inc. (Palvella), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...